ReviewEClinicalMedicine2024

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.

Nasreen Alfaris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.